Vimarsana
Biggest News Aggregation in the World

Cosmo Feilding Mellen News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Cosmo Feilding Mellen. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Cosmo Feilding Mellen Today - Breaking & Trending Today

5-MeO-DMT Study Shows Relief For Treatment-Resistant Depression - Vimarsana News

5-MeO-DMT Study Shows Relief For Treatment-Resistant Depression

5-MeO-DMT used for depression for those who do not respond to traditional and first-line therapeutics; results show a rapid antidepressant response in 55% of patients.

Source: forbes.com
Intranasal 5-MeO-DMT Clinical Trial Offers Hope For Treatment-Resistant Depression - ATAI Life Sciences (NASDAQ:ATAI) - Vimarsana News

Intranasal 5-MeO-DMT Clinical Trial Offers Hope For Treatment-Resistant Depression - ATAI Life Sciences (NASDAQ:ATAI)

Investment To Reinforce Atai's 'Largest And Most Diverse' Clinical-Stage Psychedelics Portfolio In The Sector - GH Research (NASDAQ:GHRS), ATAI Life Sciences (NASDAQ:ATAI) - Vimarsana News

Investment To Reinforce Atai's 'Largest And Most Diverse' Clinical-Stage Psychedelics Portfolio In The Sector - GH Research (NASDAQ:GHRS), ATAI Life Sciences (NASDAQ:ATAI)

Biopharma and resources-pooling company Atai Life Sciences (NASDAQ: ATAI) has invested a total of $50 million in Beckley Psytech Ltd., a U.K.-based clinical-stage biotech advancing short-duration psychedelics for neuropsychiatric conditions.

Atai Life Sciences Announces Strategic Investment in Beckley Psytech to Accelerate the Clinical Development of Short-Duration Psychedelics - Vimarsana News

Atai Life Sciences Announces Strategic Investment in Beckley Psytech to Accelerate the Clinical Development of Short-Duration Psychedelics

Strategic investment in Beckley Psytech reinforces atai’s position as the biopharmaceutical company with the largest and most diverse portfolio of clinical-stage psychedelic candidatesTwo...

First Patient Dosed in Beckley Psytech's International Phase IIb Study of BPL-003, a Novel Synthetic Intranasal Formulation of 5-MeO-DMT, for Treatment Resistant Depression (TRD) | Region - Vimarsana News

First Patient Dosed in Beckley Psytech's International Phase IIb Study of BPL-003, a Novel Synthetic Intranasal Formulation of 5-MeO-DMT, for Treatment Resistant Depression (TRD) | Region

OXFORD, England--(BUSINESS WIRE)--Oct 24, 2023--